US 9,175,310 B2 · Rapid and prolonged immunologic-therapeutic

Abstract

The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

Claims14

Dependent claims

A method for an immune response against of influenza infection in a mammalian subject in need thereof comprising:

administering intranasally, during a period within 1-2 days before exposure to an influenza virus, an effective amount of at least 107 infectious units (ifu) of E1 and/or E3 deleted adenovirus that contains and expresses an influenza virus antigen codon optimized for the mammalian subject,
wherein a protective response against the influenza virus begins within twenty four hours of administration and lasts at least 21 days providing treatment to the mammalian subject at risk of the influenza infection.

Dependencies are inferred from the claim text.

Rapid and prolonged immunologic-therapeutic

Life of this patent

Rapid and prolonged immunologic-therapeutic

Life of this patent

Abstract

Claims14